Comparing the current results to its competitors, Tiziana Life Sciences Ltd reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Tiziana Life Sciences Ltd's competitors' average revenue growth of 10.04 %, achieved in the same quarter.
Tiziana Life Sciences Ltd, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 38.06 %
Tiziana Life Sciences Ltd's Comment on Competition and Industry Peers
Tiziana Pharmaceuticals operates in a competitive environment that includes large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies, and both public and private research organizations. Its lead asset, Foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS), Amyotrophic Lateral Sclerosis (ALS), Multiple System Atrophy (MSA), and Alzheimer's Disease (AD). Other therapies in development for these conditions include a non-fully human monoclonal antibody with a different mechanism of action for na-SPMS, as well as various non-monoclonal antibody treatments targeting na-SPMS, ALS, MSA, and AD. Competitors and their strategic partners often possess significantly greater financial, technical, research and development, clinical, marketing, and manufacturing resources. Industry mergers and acquisitions may further consolidate these resources among fewer entities, which could reduce or eliminate Tiziana's commercial opportunities if competitors develop safer or more effective products.
November 19, 2024
New York, Nov. 19, 2024 Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a pioneering biotechnology company focused on developing transformative immunomodulation therapies, announced a significant milestone in their journey towards combating Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig s disease. The ALS Association has approved Tiziana’s grant application under the prestigious Hoffman ALS Clinical Trial Awards Program, earmarking funding for a groundbreaking clinical trial involving the company s lead development candidate, intranasal foralumab. Understanding the Grant and Clinical Trial sThe grant from the ALS Association will facilitate a 20-patient clinical trial aimed at assessing t...
May 13, 2024
Tiziana Life Sciences, a biotechnology company specializing in immunomodulation therapies, has filed for Orphan Drug Designation for intranasal foralumab in the treatment of non-active secondary progressive multiple sclerosis (na-SPMS). This groundbreaking therapy has demonstrated effectiveness in clinical and non-clinical evidence, supported by studies conducted at the Brigham and Women s Hospital in Boston, Massachusetts.Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis:Tiziana Life Sciences recently announced the dosing of the first patient in its Phase 2a study to compare two doses of intranasal foralumab with a placebo in na-SPMS patients. This double-blind, placebo-controlled trial involves ...
April 25, 2024
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal ForalumabNEW YORK, April 25, 2024 - Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (Tiziana or the Company), a biotechnology company renowned for its pioneering immunomodulation therapies utilizing innovative drug delivery systems, has unveiled groundbreaking statistical data demonstrating significant improvements in White Matter Z-scores in patients with non-active secondary progressive multiple sclerosis (na-SPMS) following treatment with nasal foralumab. These White Matter Z-scores serve as a crucial metric in neuroimaging studies, assessing the structural integrity of the brain and detecting...
April 22, 2024
Therapeutic Potential of Foralumab in Treating Fatigue in Non-Active Secondary Progressive Multiple Sclerosis PatientsFatigue is a common symptom experienced by individuals with multiple sclerosis (MS), particularly those with non-active secondary progressive MS (na-SPMS). It significantly impacts the quality of life and overall functionality of these patients. Tiziana Life Sciences, Ltd. has been conducting an Expanded Access Program (EAP) to study the efficacy of foralumab, a novel immunomodulation therapy, in the management of fatigue among na-SPMS patients. This article presents additional positive clinical results from the EAP, highlighting the significant improvement in fatigue observed after six mont...
New York, November 30, 2023 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA), a leading biotechnology company focused on developing innovative immunomodulation therapies through novel drug delivery methods, announced today that it has successfully enrolled and dosed four additional patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Expanded Access (EA) Program at Brigham and Women s Hospital, a founding member of the Mass General Brigham Healthcare System. With these new enrollments, a total of ten patients are now being closely monitored in the EA Program. Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, wherein the immune s...
Publicly Traded Peers of Tiziana Life Sciences Ltd
Astrazeneca Plc Share Performance
+1.79%
One Year
Astrazeneca Plc
Profile
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Sources:
Tiziana Life Sciences Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tiziana Life Sciences Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
